These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 10741696

  • 1. Expression of ERCC1 antisense RNA abrogates gemicitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair.
    Yang LY, Li L, Jiang H, Shen Y, Plunkett W.
    Clin Cancer Res; 2000 Mar; 6(3):773-81. PubMed ID: 10741696
    [Abstract] [Full Text] [Related]

  • 2. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines.
    van Moorsel CJ, Pinedo HM, Veerman G, Bergman AM, Kuiper CM, Vermorken JB, van der Vijgh WJ, Peters GJ.
    Br J Cancer; 1999 Jun; 80(7):981-90. PubMed ID: 10362105
    [Abstract] [Full Text] [Related]

  • 3. Synergistic interaction between cisplatin and gemcitabine in vitro.
    Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Peters GJ.
    Clin Cancer Res; 1996 Mar; 2(3):521-30. PubMed ID: 9816199
    [Abstract] [Full Text] [Related]

  • 4. Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell lines.
    Peters GJ, Van Moorsel CJ, Lakerveld B, Smid K, Noordhuis P, Comijn EC, Weaver D, Willey JC, Voorn D, Van der Vijgh WJ, Pinedo HM.
    Int J Oncol; 2006 Jan; 28(1):237-44. PubMed ID: 16328001
    [Abstract] [Full Text] [Related]

  • 5. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.
    Lord RV, Brabender J, Gandara D, Alberola V, Camps C, Domine M, Cardenal F, Sánchez JM, Gumerlock PH, Tarón M, Sánchez JJ, Danenberg KD, Danenberg PV, Rosell R.
    Clin Cancer Res; 2002 Jul; 8(7):2286-91. PubMed ID: 12114432
    [Abstract] [Full Text] [Related]

  • 6. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines.
    Selvakumaran M, Pisarcik DA, Bao R, Yeung AT, Hamilton TC.
    Cancer Res; 2003 Mar 15; 63(6):1311-6. PubMed ID: 12649192
    [Abstract] [Full Text] [Related]

  • 7. Combination chemotherapy studies with gemcitabine and etoposide in non-small cell lung and ovarian cancer cell lines.
    van Moorsel CJ, Pinedo HM, Veerman G, Guechev A, Smid K, Loves WJ, Vermorken JB, Postmus PE, Peters GJ.
    Biochem Pharmacol; 1999 Feb 15; 57(4):407-15. PubMed ID: 9933029
    [Abstract] [Full Text] [Related]

  • 8. Influence of genetic markers on survival in non-small cell lung cancer.
    Rosell R, Taron M, Camps C, López-Vivanco G.
    Drugs Today (Barc); 2003 Oct 15; 39(10):775-86. PubMed ID: 14668933
    [Abstract] [Full Text] [Related]

  • 9. Cisplatin-induced apoptosis in 43-3B and 27-1 cells defective in nucleotide excision repair.
    Dunkern TR, Fritz G, Kaina B.
    Mutat Res; 2001 Sep 04; 486(4):249-58. PubMed ID: 11516928
    [Abstract] [Full Text] [Related]

  • 10. Interaction between cisplatin and gemcitabine in vitro and in vivo.
    Peters GJ, Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Braakhuis BJ.
    Semin Oncol; 1995 Aug 04; 22(4 Suppl 11):72-9. PubMed ID: 7481849
    [Abstract] [Full Text] [Related]

  • 11. Selective cell kill of the combination of gemcitabine and cisplatin in multilayered postconfluent tumor cell cultures.
    Padrón JM, van Moorsel CJ, Bergman AM, Smitskamp-Wilms E, van der Wilt CL, Peters GJ.
    Anticancer Drugs; 1999 Jun 04; 10(5):445-52. PubMed ID: 10477163
    [Abstract] [Full Text] [Related]

  • 12. Effect of gemcitabine and cis-platinum combinations on ribonucleotide and deoxyribonucleotide pools in ovarian cancer cell lines.
    Van Moorsel CJ, Smid K, Voorn DA, Bergman AM, Pinedo HM, Peters GJ.
    Int J Oncol; 2003 Jan 04; 22(1):201-7. PubMed ID: 12469205
    [Abstract] [Full Text] [Related]

  • 13. Inhibition by 5-fluorouracil of ERCC1 and gamma-glutamylcysteine synthetase messenger RNA expression in a cisplatin-resistant HST-1 human squamous carcinoma cell line.
    Fujishima H, Nakano S, Masumoto N, Esaki T, Tatsumoto T, Kondo T, Niho Y.
    Oncol Res; 1997 Jan 04; 9(4):167-72. PubMed ID: 9268987
    [Abstract] [Full Text] [Related]

  • 14. Defects in interstrand cross-link uncoupling do not account for the extreme sensitivity of ERCC1 and XPF cells to cisplatin.
    De Silva IU, McHugh PJ, Clingen PH, Hartley JA.
    Nucleic Acids Res; 2002 Sep 01; 30(17):3848-56. PubMed ID: 12202770
    [Abstract] [Full Text] [Related]

  • 15. Arabinosyl-2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair.
    Yang LY, Li L, Keating MJ, Plunkett W.
    Mol Pharmacol; 1995 May 01; 47(5):1072-9. PubMed ID: 7746274
    [Abstract] [Full Text] [Related]

  • 16. Cell cycle checkpoint abrogator UCN-01 inhibits DNA repair: association with attenuation of the interaction of XPA and ERCC1 nucleotide excision repair proteins.
    Jiang H, Yang LY.
    Cancer Res; 1999 Sep 15; 59(18):4529-34. PubMed ID: 10493501
    [Abstract] [Full Text] [Related]

  • 17. Action of 2',2'-difluorodeoxycytidine on DNA synthesis.
    Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W.
    Cancer Res; 1991 Nov 15; 51(22):6110-7. PubMed ID: 1718594
    [Abstract] [Full Text] [Related]

  • 18. Modulation of drug resistance mediated by loss of mismatch repair by the DNA polymerase inhibitor aphidicolin.
    Moreland NJ, Illand M, Kim YT, Paul J, Brown R.
    Cancer Res; 1999 May 01; 59(9):2102-6. PubMed ID: 10232595
    [Abstract] [Full Text] [Related]

  • 19. Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins.
    Sergent C, Franco N, Chapusot C, Lizard-Nacol S, Isambert N, Correia M, Chauffert B.
    Cancer Chemother Pharmacol; 2002 Jun 01; 49(6):445-52. PubMed ID: 12107548
    [Abstract] [Full Text] [Related]

  • 20. Schedule-dependent pharmacodynamic effects of gemcitabine and cisplatin in mice bearing Lewis lung murine non-small cell lung tumours.
    van Moorsel CJ, Pinedo HM, Smid K, Comijn EM, Voorn DA, Veerman G, Lakerveld B, Van der Vijgh WJ, Giaccone G, Postmus PE, Peters GJ.
    Eur J Cancer; 2000 Dec 01; 36(18):2420-9. PubMed ID: 11094319
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.